The Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes trial confirmed the SGLT2 inhibitor canagliflozin had cardiovascular and renal benefits (Neal et al., 2017). Here, SLC5A2 is linked to type 2 diabetes mellitus.